EP1355661A2 - Tumor vaccine - Google Patents

Abstract

The invention relates to a vaccine and to the production thereof for the treatment of patients suffering from defined tumor diseases. The inventive vaccine consists of tumor cells that were transfected ex vivo with expression constructs that code for certain cytokines. Immunostimulating oligodeoxyribonucleotides are used as the adjuvants.

Description

 tumor vaccine

description

The invention relates to a vaccine for the therapeutic treatment of tumor diseases, and to a method for producing such a vaccine.

Tumor diseases are one of the main causes of death in the industrialized world. Established methods of treating cancer, such as surgical removal, radiation and chemotherapy, often lead at best to a temporary reduction in the disease.

Against this background, along with a deeper understanding of the molecular mechanisms of cell metabolism and the signal transduction pathways that underlie cell division and the targeted cell death, approaches to the treatment of tumor diseases that have an immunological or gene therapy background (Greten and Jaffee, 1999, J. Clin. Oncol. 17: 1047-1060).

The basic idea of the immunological approaches is to present the tumor as an aberrant cell to the immune system, and, based on the expectation that it is the natural task of the immune system to recognize and destroy such aberrant cells, to initiate these mechanisms also against the tumor cell population that is the reason for the disease ,

State of the art

It is known that the immunological cell system is under equilibrium between cell degradation and cell build-up under physiological conditions. The proliferation, differentiation, function and regulation, the cell-cell contact and the The formation of immunological recognition structures is controlled by cytokines.

Among other things, cytokines control the growth and differentiation of leukocytes, the initial phase of the immune response, and they stimulate and suppress effector functions of the immune system.

Numerous cytokines are known from the prior art, for example interleukin 1: a lymphocyte-activating factor, interleukin 2: a T cell growth factor, interleukin 3: a mast cell growth factor, interleukin 4: a B cell stimulating factor, interleukin 7 and other interleukins as well as the granulocyte / macrophage colony stimulating factor (GM-CSF), the tumor necrosis

Factor (TNF), the family of interferons and numerous others.

US 5,589,466 discloses immunizing mammals by injecting DNA or RNA, the DNA or RNA molecules being transported in constructs. It is described that the constructs used are free of viral particles.

It is known from US Pat. No. 5,681,562 to inject cells with certain cancers which are transfected with DNA or RNA encoding interleukins. The patient's immune system should thus be stimulated against antigens from tumors. The patent describes experiments in which fibroblasts from mice were transfected by retroviral vectors coding for IL-2. Also described is the in vivo trial in which the effectiveness of the treatment was tested on a murine colon carcinoma model. The mice to whom transfected fibroblasts s.c. injected developed a significantly slower tumor growth compared to control groups. In in-vitro experiments with human transfected fibroblasts, a significantly increased level was also found

IL-2 expression levels can be determined. In addition to the lack of clinical data that go beyond the mouse model, the viral vectors used as the expression vector can be regarded as less advantageous. Due to the instability of the attenuated vaccine strain, a conversion back into a virulent strain cannot be ruled out. In addition, the viral components themselves can have an immunogenic effect, which leads to a reduction in their effectiveness by the patient's immune system. These risks are widely used as ten leads. These risks are largely opposed to widespread use as a gene therapy vector.

The inventors of the present application were able to show that the transfer of expression plasmids for human interleukin 7 (IL-7) in tumor cells leads to an increased sensitivity to effector cells of the immune system, especially with autologous transfer (Finke et al., 1997, Cancer Gene Ther. 4: 260-268).

Several publications show that the best therapeutic results are achieved by combining cytokine genes with the growth factor GM-CSF (Paillard, 1998, Hum. Gene Ther. 9: 2457-2458; Schadendorf et al., 1995, J. Mol. Med 73: 473-477). The activation of antigen-presenting dendritic cells and the stimulation of an effector cell population obviously play an important role in this.

So far, however, it is unclear which cytokine genes in combination with GM-CSF are able to trigger the most effective anti-tumor immune response.

Experiments in mice showed that vaccination with

Expression constructs encoding IL-7 showed an anti-tumor effect (Miller et al., 1993, Blood 18: 3686-3694; Murphy et al., 1993, J. Clin. Invest. 92: 1918-1924).

However, real therapeutic successes have not yet been published in the mouse model.

Furthermore, it has been observed in attempts to stimulate immune responses by gene therapy with plasmid DNA or oligonucleotide sequences that certain nucleic acid sequences which have CpG motifs (CpG = unmethylated cytosine guanosine) can have an enormous immunostimulatory effect (Schmidt-Wolf et al., 1989, J. Immunol. Methods 125: 185-189; Roman et al., 1997, Nat. Med. 3: 849-854). For this reason, immunostimulatory sequences (IS) were used early on as adjuvants in DNA-based immunization protocols against infectious agents (Sato et al., 1996, Science 273: 352-354). Mouse experiments showed that the Administration of CpG-rich DNA sequences leads to a strong activation of the B cells and stimulates the expression of certain cytokines, for example IL-6 and GM-CSF. The teaching of the use and production of immunostimulatory, CpG-containing ISS is comprehensively explained in WO 98/18810.

From WO 00/04918 it is known to transfect tumor cells with genes, coding for example for interferon-gamma and GM-CSF. Plasmids are used as expression vectors. This document shows a concept for treating tumor diseases by immunotherapy. Meaningful in vivo or in vitro data or clinical results that prove the effectiveness of the claimed vaccine are not shown. It should be noted that these plasmid-based vectors are not suitable for use in human gene therapy without reservation, since they carry, in addition to the therapeutic sequences, genetic functional units which they require for their replication. In addition, they have antibiotic resistance genes that are essential for their selection. So there is a permanent expression of therapeutically undesirable mammals - or bacterial proteins.

Despite many years of research and promising approaches, it has so far not been possible to develop an effective immune-based therapy against tumor diseases.

The object of the invention is to provide a vaccine as a medicament for the treatment of diseases related to cytokines, such as cancer, which can be used specifically and efficiently and in particular leads to the induction of tumor-specific immune responses. A corresponding method for producing such a vaccine is also to be provided.

Solution to the problem and advantages of the invention

The present invention solves this technical problem by providing a vaccine for the treatment of patients with defined tumor diseases, consisting of tumor cells from a patient, these tumor cells previously ex-vivo with code for interleukin-7 (IL-7) and macrophage-activating factor GM-CSF - Rende expression constructs were transfected. Under transfection, the bringing nucleic acid sequences are understood by means of biological, chemical or physical methods, as a result of which there is a sustained or temporary expression of proteins encoded by these sequences.

In addition, immunostimulatory nucleic acid sequences (ISS) were used as adjuvants. The CpG motifs of the ISS cause an increase in the activity of NK cells and macrophages and a strong stimulation of the cellular TH1 immune response. Covalently closed ISSs with a length of 30 bp are preferably used, as described in WO 01/07055. The constructs according to the invention are referred to below as d-SLIM (double stem-loop immunomodulating oligodeoxyribonucleotides).

Surprisingly, it was found that the combination of nucleic acids which code for a macrophage activating factor and an interleukin in a cell in which these nucleic acids are expressed leads to effective and specific vaccine protection being able to be achieved.

Plasmids can be used as DNA expression constructs; according to the invention, minimalistic immunologically defined gene expression constructs are preferably used. These are linear, covalently closed expression cassettes which consist only of the CMV promoter, an intron, the corresponding gene sequence and a polyadenylation sequence. These covalently closed minimalistic DNA constructs are referred to below as MIDGE ^® vectors (MIDGE ^® : MINIMALISTIC jMMUNO-LOGICALLY DEFINED GENE EXPRESSION VECTORS); see. EP 0 941 318 B1. The MIDGE constructs have the advantage that they can be used without structures that are not essential for the therapeutic effect, which ultimately avoids the disadvantages of gene transports of viral origin.

The invention thus relates to the combination of at least two expressible nucleic acids, selected from the group of nucleic acids which code for at least one interleukin and at least one macrophage activating factor?

The two nucleic acids can be introduced in one or more (preferably two) expression constructs. In connection with the present invention, a number of general terms are understood below as follows:

In connection with the present invention, the term treatment means the prophylactic and / or therapeutic effect of a medicinal substance.

In connection with the present invention, the term macrophage-activating factor and / or interleukin relates both to naturally occurring macrophage-activating factors and / or interleukins and to all modifications, mutants or derivatives of the macrophage-activating factors and / or interleukins, macropage-activating factors produced by recombination techniques and / or interleukins which contain amino acid modifications such as inversions, deletions, insertions, additions, etc., provided that at least some of the essential functions of the wild-type macrophage activating factors and / or interleukins are present. Such macrophage activating factors and / or interleukins can also include unusual amino acids and / or modifications such as alkylation, oxidation, thiol modification, denaturation and oligomerization and the like. In connection with the present invention, macrophage activating factors and / or interleukins can in particular be proteins, peptides and / or fusion peptides which, in addition to other proteins, peptides or parts thereof, contain macrophage activating factors and / or interleukins in whole or in part. In a further embodiment of the present invention, the macrophage activating factors and / or interleukins are shortened forms of the naturally occurring macrophage activating factors and / or interleukins.

According to the invention, it is provided that a tumor cell comprises at least one nucleic acid molecule which codes together for a macrophage activating factor (preferably GM-CSF) and an interleukin (preferably interleukin-7). These tumor cells come from patients with a defined tumor disease, such as, for example, preferably renal carcinoma, malignant melanoma and / or colon carcinoma. The DNA expression constructs which lead to expression in the cells are introduced into these cells by means of biological, chemical and / or physical transfection methods. The transfected cells serve as vaccines and are applied to patients with the same clinical picture, to them themselves or the cells were previously taken from other patients with the same clinical picture. The body of the cell extraction can be the body to be treated with the drug; however, the body of the cell extraction cannot be the body to be treated with the drug.

The cells to be treated can come from a single body or can be pooled from several bodies with the same clinical picture.

In a further advantageous embodiment of the invention, the vaccine can comprise at least one immunomodulating oligodeoxyribonucleotide. The immunomodulating oligodeoxyribonucleotide comprises a circular strand of deoxyribonucleic acid with a partially complementary, antiparallel base sequence. In a particularly preferred embodiment, the immunomodulating oligodeoxyribonucleotide is dumbbell-shaped.

The immunostimulatory nucleic acid sequences ("ISS") are only a few bases long and do not act via the expression of proteins encoded on them. Most known immunomodifying short oligodeoxyribonucleotide sequences ("ODN") contain an unmethylated cytosine guanosine motif. In particular, double-stranded molecules with the relevant immunostimulatory sequence in the double-strand region exert a noteworthy stimulatory effect. The short deoxyribonucleic acid molecules consist in particular of a ring-shaped, closed sequence of nucleoside residues. Such ring-shaped closed deoxyribonucleic acid molecules can advantageously be obtained from open-chain deoxyribonucleic acid molecules which have a partially self-complementary sequence and which can form an intermediate stable hybrid with one another or with a second molecule. The molecule can also advantageously be obtained by intramolecular ligation of a molecule which has at least two self-complementary regions which are separated by only one gap in the phosphate backbone. The molecules obtained in this way have no free 5 'or 3' ends and are therefore not accessible to exonucleases.

The immunomodulating oligodeoxyribonucleotide can preferably comprise a sequence with the base sequence N ¹ N ² CGN ³ N ⁴ , where N ¹ N ^{2 is} an element selected from the group comprising GT, GG, GA, AT or AA, N ³ N ^{4 is} an element out- is selected from the group comprising CT or TT, and C is deoxycytosine, G deoxyguanosine, A deoxyadenosine and T deoxythymidine. The sequence with the base sequence N ¹ N ² CGN ³ N ⁴ is preferably positioned in the single-stranded region of the oligodeoxyribonucleotide. The oligodeoxyribonucleotide advantageously comprises 20 to 200 nucleotides. An advantage of the invention is that the selected and used nucleic acid sequences (d-SLIM) additionally have an enormous immunostimulatory effect. These immunostimulatory nucleic acids have their effect according to the invention, for example in the vaccines, in particular via a secondary stimulation of the release of co-stimulatory factors.

The transfection into a cell preferably takes place. The cells are expediently an allogeneic cell, a heterotopic cell, a syngeneic cell, a xenogeneic cell, an autologous cell, a virus-infected cell, a degenerate cell, a transformed cell, an antibody-loaded cell and / or an undifferentiated cell. The cells are preferably mammalian cells, especially human cells.

In a particularly preferred embodiment of the invention, the nucleic acid molecule is a DNA, in particular a cDNA or a genomic DNA. Of course, it can also be advantageous for the nucleic acid molecule to be an RNA.

Biological, chemical and / or physical methods which belong to the prior art can be used for the transfection, for example transfection by means of ballistic transfer, polycation transfection, calcium phosphate precipitation, microinjection, protoplast fusion, liposome fusion, viral transfection systems, lipofection and / or Electroporation in vivo and / or in vitro. In a preferred embodiment of the invention, the transfection takes place by means of ballistic transfer.

Biological transfection methods such as receptor-mediated gene transfer are further advantageous methods. Here, for example, a DNA

Expression construct that codes for at least one macrophage activatable factor and at least one interleukin, covalently linked to an oligopeptide, which is preferably the nuclear localization signal (NLS) from Simian Virus SV-40.

The use of further, partly synthetically produced peptides makes it possible to further increase the transfection efficiency in cells and liposomes. This method is particularly suitable for cell-specific in vivo gene transfer after intravenous administration.

Further advantageous embodiments of the invention result from the subclaims and the description. The surprising effect of the medicament according to the invention (as a vaccine for carcinoma therapy) and the method according to the invention are clear from the tables and the exemplary embodiments; it shows:

Table 1 Characteristics of the 10 patients included.

The age range was 46 to 69 years. Eight patients were male, two female. One patient suffered from colon cancer, four from malignant melanoma and five patients from renal cell carcinoma. Renal cell carcinomas have very poor healing prospects. The location of the metastases is also shown.

Table 2 shows the transfection efficiency. After in vitro transfection with expression constructs coding for IL-7 and GM-CSF, all cells secrete the cytokines IL-7 and GM-CSF.

Table 3 shows the cytokine profiles of the sera of the

Patients. The levels of IL-7, interferon-gamma and TGF-ß (Transforming Growth Factor-ß) were determined in the sera. The serum level for IL-7 and interferon-gamma was measurably increased. Table 4 shows the expressed surface antigens of the peripheral blood lymphocytes (PBL). In particular, there was a significant increase in CD8,

CD3 and CD 56 positive PBL. The cytotoxicity of these cells increased significantly as a result of the treatment.

Table 5 shows the increase in the cytotoxic activity of the

PBL as a result of the treatment. The cytotoxicity of the PBL increased significantly as a result of the treatment (p = 0.01).

The concept of the underlying clinical study has been published (Schmidt-Wolf et al., 1994). In the study carried out at the time, patients with IL-7, IL-12 and GM-CSF were treated with gene therapy. In contrast to the present invention, the patients were not treated with a combination of the cytokine genes, but each cytokine was used individually in a patient group as a vaccine. A significant treatment success was not visible. Only the patients treated with GM-CSF showed an immunological reaction, which was not, however, reflected in a measurable clinical reaction.

According to the invention, ten patients with metastatic solid tumors were taken from tumor material, these were transfected outside the body with expression vectors coding for IL-7 and GM-CSF and these cells were fed back to the patient after cultivation ex vivo and after the addition of immunostimulatory sequences. The patients received four subcutaneous injections on the 0th, 14th, 28th and 56th day.

All patients were in an advanced phase of the disease at the start of treatment. One patient had colon cancer, four patients had malignant melanoma and five patients had renal cell carcinoma (patient characteristics see Table 1). Renal cell carcinoma diseases belong to the group of those with very poor healing prospects among neoplasias. The patients were followed for 84 days. Table 1 Characteristics of the patients

In-vitro tests for cytokine level determination were carried out; there was increased secretion of IL-7 and GM-CSF in all transfected lines (see Table 2).

Table 2 Cytokine values in picogram (pg) after transfection of the primary culture (transfection efficiency)

nb not determined The vaccine according to the invention made from modified tumor cells produced by the method according to the invention shows surprising effects. It is advantageous that the vaccine according to the invention induces a tumor-specific immune response. For example, the serum level of IL-7 and interferon gamma of the patients after treatment was measurably increased (see Table 3). There were no significant differences in the levels of cytokines before and after treatment. In particular, there was a significant increase in CD8 and CD3 positive peripheral blood lymphocytes (PBL). The cytotoxicity of this cell population increased significantly during the treatment from 21.5% to 25.6% (calculated from mean values on the 84th day) in all patients after completion of the treatment. The significance was p = 0.03 (see Table 4). The increase in PBLs that expressed CD 56 was comparable from 16.3% to 27.5% (calculated from mean values on the 84th day). Here, too, the significance was p = 0.03 (see Table 4).

Table 3 Results of the cytokine determination (ELISA)

Table 4 Expressed surface antigens of peripheral blood lymphocytes (PBL)

To compare the change in the cytotoxicity of the PBL, these were taken from the patients before, during and after the treatment. Remarkably, the cytotoxicity of PBL increased significantly during treatment p = 0.01 (see Tables 4 and 5).

Table 5 Increase in peripheral blood lymphocyte (PBL) cytotoxicity during treatment

The clinical results are mainly based on computed tomography (CT) evaluations. According to the World Health Organization (1979), the following formulations should apply: a partial response (PR) refers to the decline in detectable tumor areas by more than 50% in the past four weeks and the suppression of new tumor areas. A stable disease course (SD) is to be understood as the steady state. All patients tolerated the treatment well and there were no undesirable side effects.

Five out of ten patients showed a clinically significant response. This means that two patients showed a stable course (SD) after treatment, one patient a mixed response (MR), i.e. H. a progression of

Metastasis in the abdomen and a decrease in metastases in the lungs and a patient developed a partial response (PR). A complete decrease (CR) in the focus of the tumor was observed in one patient.

Remarkably, four of the successfully treated patients came from the group with the initial diagnosis of renal cell carcinoma. The success of the treatment means that there was a minimal response in one patient, a stable disease course (SD) in two patients and even a complete response (CR) in one patient.

The patient with the complete reaction showed the following initial picture: metastases up to 3 cm in size in the lungs, a 4x4x3 cm size metastasis infiltrated the neighboring rib, metastases in ribs IV and VII and a large kidney tumor. After its removal, the kidney tumor was checked for confirmation of the diagnosis of renal cell carcinoma. Part of the tumor was used for vaccine production. After four vaccinations with transfected cells, a decrease in metastases in the lungs and bones was observed. At the

Patients showed a complete decrease (remission) of the tumor focus for more than 24 months (CT images not shown).

Five of all treated patients showed progression of the disease (progressive disease).

These results show that the treatment of tumor diseases in the advanced stage with the subject matter of the invention is capable of generating in vivo anti-tumor-specific immune responses and leads to measurable clinical results. In light of the expected conditions for the underlying disease, these results show the impressive effectiveness of the treatment. This vaccination could be a promising form of therapy, especially for patients in the early stages of a tumor disease.

The invention will be explained in more detail below with the aid of an example, without the invention being restricted to this example.

Treatment of metastatic colorectal cancer, renal cell carcinoma and malignant melanoma

Selection of patients: Patients with metastatic colon carcinoma, renal cell carcinoma or malignant melanoma, between the ages of 18 and 70, and a Kamofsky index of 70-100 were eligible for admission. Exclusion criteria were: previous cytokine treatment or chemotherapy that was less than 28 days ago, creatine values above 265μmol / l, bilirubin values above 51μmol / l, uncompensated heart failure, ventricular rhythm disorders, severe psychiatric diseases, active hepatitis A, B or

C, HIV infection.

Treatment: In addition to the medical history, the following parameters were determined before the start of treatment: physical examination, hematology (hemoglobin, hematocrit, leukocytes and platelet count), chemical blood values and urine analysis. Blood was taken for immune status determination. DHT (Delayed type hypersensitivity) skin tests were carried out with the Multitest Merieux Test (Leimen, Germany). X-rays of the upper body and computed tomography of the upper body and abdomen were taken. The patients received four subcutaneous injections with at least 1x10 ⁶ cells of their previously ex-vivo treated tumor cells. Comprehensive immunological examinations, haematological examinations and rough clinical examinations (physical examination, ultrasound examination and examination of the abdomen, if necessary) were repeated on the 14th, 28th and 56th day. A complete clinical and immunological examination, comparable to the selection examination carried out at the beginning, took place on the 84th day. Preparation of the tumor cell suspension

The tumor cell suspension was treated as described for primary cell cultures (Finke, et al., 1997, Cancer Gene Ther. 4: 260-268). Tumor samples taken sterile from the patients were immediately transferred to ice-cooled suspension medium in 50 ml Falcon centrifuge tubes with screw caps. The transport of the cooled samples to the laboratory, in which the ex-vivo treatment of the patient cells took place, took between 1-3 hours.

All of the following procedures were carried out according to work instructions (SOP). All preparations of the tumor cells were carried out in class A and B (clean room) environment under GMP-analogous conditions and S2 safety classification in accordance with the German Genetic Engineering Act. Only GMP certified chemicals, culture media, solvents and materials were used. Sterile tests were carried out by a certified laboratory in accordance with DAB 10 V.2.1.1. Contamination with mycoplasma was tested using a commercial PCR kit StrataClean ™ (StrataGene).

As an input contamination control of the tumor samples, aliquots of the suspension medium were kept for sterility tests. The tumor material was washed twice with 50 ml PBS (without Ca ²⁺ and Mg ²⁺ , Bio Whittaker) containing 50 μg / ml gentamycin (Bio Whittaker) and 1 μg / ml amphotericin B (Gibco) at 4 ° C. Obvious non-tumor tissue and dead tissue were removed as far as possible with scalpel or scissors. The tumor tissue was then transferred to 140 mm Petri dishes (Falcon) containing approximately 20 ml (depending on the tumor size) of suspension medium and cut into small pieces. Cell sieves of 100 μm, 70 μm, and 40 μm pore diameter (Falcon) after decreasing size were in 50 ml centrifuge tubes (Falcon), the tissue pieces were pressed through these sieves by mechanical pressure. During this process the sieves were continuously rinsed with suspension medium. Tissue breakdown into individual cells was monitored microscopically and sieving repeated if necessary. The tumor cells were obtained by centrifugation (350xg, 4 ° C, 7 min) and washed by resuspension and centrifugation in PBS (without Ca ²⁺ and Mg ² ) at 4 ° C. The cells were counted and their size distribution measured (Multisizer II, Sigma). The Vitality was checked using a flow cytometer using propidium iodide staining. A cell culture was established from part of the cells. Aliquots of the suspension were saved for a sterility test.

Suspension medium for renal carcinoma cells: undiluted L-15 medium (BioWhittaker), 10% FCS (BioWhittaker), 1x MEM vitamins (Biochrom), 1x insulin transferrin-Selenium-X (Gibco), 1mM L-glutamine (BioWhittaker), 1g / l NaHCO3 (Gibco), 1g / l glucose for DMEM (Gibco), 50μg / μl gentamicin (BioWhittaker).

Suspension medium for malignant melanoma cells: undiluted RPMI medium 1640 (with ultraglutamine, BioWhittaker), 10% FCS (BioWhittaker), 50μg / μl gentamicin (BioWhittaker)

Minimalistic immunologically defined gene expression constructs (MIDGE)

Two covalently closed minimalistic DNA expression vectors, called "MIDGE", were used. One expression vector was used for the expression of human interleukin-7 (IL-7), the other for the expression of the human granulocyte macrophage colony stimulating factor (GM-CSF). The MIDGE vectors were synthesized according to the SOP regulation and in the class B corresponding laboratory with subsequent quality control.

The coding gene sequence for IL-7 and GM-CSF was amplified from human white blood cell mRNA using reverse transcriptase-PCR (RT-PCR). The amplificates were inserted into the plasmid pMOK, a pUC19 derivative, between the SstI and Kpnl interfaces. In addition to the strong "early immediate promoter" from the CMV virus, PMOK has an intron and a polyadenylation sequence from the SV40 virus (MOLOGEN, Berlin, Germany).

The plasmid pMOK was completely digested with the restriction enzyme Eco31 I overnight at 37 ° C. Restriction digestion generated two DNA fragments. One consisted of the kanamycin resistance gene and other sequences necessary for the propagation of the plasmid in bacteria. The other fragment consisted of the sequences that were to become part of the MIDGE DNA: enhanced CMV promoter, chimeric intron, the corresponding gene sequence and the polyadenylation sequence from SV-40. The 5 'phosphorylated hairpin-shaped oligodeoxynucleotides (TIB-MolBiol, Berlin) became 5' -PH-GGG AGT CCA GTT TTC TGG AC-3 'and 5' PH-AGG GGT CCA GTT TTC TGG AC-3 using the enzyme T4-DNA ligase 'Ligated in the presence of the restriction enzyme Eco31 I overnight at 37 ^D C to the DNA fragment forming the MIDGE DNA. The

The reaction was stopped by heating to 70 ° C. The resulting mixture of nucleic acids was treated with the enzyme T7 DNA polymerase. The MIDGE DNA was purified by anion exchange chromatography and precipitated with isopropanol (cf. EP 0 941 318 B1).

Double-stranded immunolatory oligodeoxynucleotides (d-SLIM)

Double-stranded immunomodulators d-SLIMs of the ISS30 type were produced after (SOP) and final quality control in the class B laboratory.

Single-stranded, hairpin-shaped, 5'-phosphorylated oligodeoxyribonucleotides (ODN) with the sequence 5'-CCT AGG GGT TAG CAC TCA TTG GAA AAC GTT CGG GGC GTT CTT GGT GGT AACC-3 'were obtained and (TIB-MolBiol, Berlin, Germany) ligated with T4 DNA ligase (MBI Fermentas, Leon Roth). After digestion of the remaining starting materials with T7 polymerase and chromatographic purification, the ODN were concentrated by ethanol and sodium-magnesium acetate precipitation and dissolved in PBS (cf. WO 01/07055)

Ballistic DNA transfer

A modified device for cell acceleration, the Biolistic PDS-1000 / He (Bio-Rad, Hercules, CA, USA), was used for the ex-vivo gene transfer into the cell nucleus of the tumor cells and the control cells. The modification relates to a device for pressure distribution (cf. EP 0732 395 B1). More than 1.5 mehr10 ⁷ cells can be treated per shot. In addition, the ballistic method is combined with the magnetic separation of the transfected cells. Although the magnetic separation was not carried out, the magnetic particles were nevertheless also introduced into the cells, since they increase the binding capacity of the gold particles for DNA. So far, this method of ballistic DNA transfer could only be used with adherently growing cells. In order to ensure the DNA transfer into the tumor cells, they were plated on a 44 mm ² polycarbonate membrane (Transwell ™, pore size 3.0 μm, from Costar). 1-2x10 ⁷ cells, depending on their size, can be loaded onto such a membrane, compared to 1-2x10 ⁶ for adherent cell cultures in culture vessels with comparable surface contents. Cell recovery and viability are significantly improved, and the treatment time is greatly reduced. Standard conditions, depending on the morphological and functional differences of the tumor line types, were developed.

The tumor cell suspensions were adjusted to a concentration of 5x10 ⁶ cells / ml in the cell suspension media. A Transwell membrane was washed with 15 ml medium from both sides for 5 min. equilibrated. The medium layer above the membrane was then removed and 2-4 ml of the tumor cell suspension was applied uniformly to the polycarbonate membrane. The cells colonized the membrane, while the suspension medium was able to drain through the membrane pores into deeper membrane layers. Excess medium in the deeper layers was removed through an opening until no liquid residues were visible over the monolayer layer. The medium below the membrane is a very important technical support during the transfection process and keeps the cells moist and viable.

15 μl of a gold suspension was pipetted onto each of the seven carrier membranes (Bio-Rad). After the gold particles (1.6 μm diameter, obtained from BioRad, Hercules, CA, USA) had settled, the supernatant was removed. For coating them with DNA and the colloidal superparamagnetic particles

(average diameter: 65 nm, Milteny GmbH), 30 μl of a 1: 3 (v / v) DNA: particle solution, with a DNA concentration of 2 mg / ml per expression vector, were pipetted onto the membranes. After stirring up the gold, the mixture was able to settle. The supernatant was removed and the coated gold particles dried at room temperature (RT).

The membranes coated with the particles were attached at a distance of 15 mm from the stop screen. The monolayer layer of the tumor cells on the Transwell membrane was placed approximately 90 mm below the stop screen. The ballistic transfer accelerated the gold particles towards the tumor cells with a pressure of 1550 psi.

Immediately after the gene transfer, the tumor cells were covered with 10 ml of prewarmed cell suspension medium and transferred into 15 ml centrifuge tubes by careful pipetting. After sedimentation of the cells at 300xg and 4 ° C for 5 min, they were dissolved in medium. Aliquots were again retained for sterility tests, cell recovery and viability tests, for FACS analyzes, and for determining cytokine expression. The transfection efficiency was determined as described (Foa et al., 1994, Nat. Immun. 13: 65-75)).

The transfected tumor cell suspension was dried again, taken up in 1.5 ml freezing medium (80% FCS, 10% DMSO, 10% suspension medium) and stored in portions of 5x10 ⁶ to 2x10 ⁷ cells in sealed 2 ml freezer tubes. The tubes were stored at -80 ° C at 1 ° C / min in liquid nitrogen.

Preparing the cells for vaccination

A tube was removed from the liquid nitrogen and thawed in a water bath with gentle shaking at 37 ° C. Then it was briefly disinfected from the outside with 70% ethanol. The thawed cell suspension was slowly and dropwise transferred into 50 ml PBS (without Ca ²⁺ and Mg ²⁺ ) at 4 ° C, and centrifuged at 300xg, at 4 ° C for 5 min. The pellet was carefully taken up in 50 ml of PBS, dried again, dissolved in 1 ml of PBS and transferred to 2 ml vessels (Biopure ™, Eppendorf). The contents were drawn onto a 1 ml syringe, sealed with a screw cap, irradiated 3 times with gamma radiation for 667 sec, which corresponded to a total dose of 105 gray. Then the syringe was transported to the clinic in a sterile, double-walled and shockproof container at 4 ° C.

Immunological studies Frozen cells were used for most studies. Therefore, cells taken at different times could be tested in one study. Fresh cells were used for the flow cytometric analyzes.

Immunofluorescence and Flow Ztometric Studies

Peripheral blood lymphocytes were treated with various monoclonal antibodies to human surface antigens. Among the antibodies were AK against human CD3, CD4, CD8, CD16, CD11a, CD14, CD19, CD25, CD28, CD45, CD54, CD56 and HLA-DR (Immunotech Hamburg, Germany). AKs from the same isotype were used as controls. The labeled cells were washed and then analyzed with the FACScan (Becton Dickinson, San Jose, CA). Irrelevant AKs were used to determine the background for this study, it was less than 2%. 10 ⁴ cells of each sample were analyzed.

Zvtotoxic test

CytoTox 96, a non-radioactive, cytotoxic test (Promega, Madison, Wisconsin) was used to determine and compare the cytotoxic activity of the peripheral blood lymphocytes. These examinations were carried out on days 0, 14, 28, 56 and 84. The test is a calorimetric alternative to the ⁵¹ chromium release test. The quantitative measure is lactate dehydrogenase (LDH), which is released by cells like ⁵¹ Cr in cell lysis. The free LDH is determined in the supernatant after a 30 minute incubation using a coupled enzymatic test. The amount of dye released is proportional to the amount of lysed cells. The absorption was measured at 490 nm. 5000 target cells were applied in triplicate in V-shaped 96-well tissue culture plates and incubated for four hours with different ratios of effector and target cells. After the incubation, 50 µl aliquots were transferred to a new 96 well plate. 50 μl of the substrate mix was added to each chamber and subsequently incubated in the dark for 30 min at RT. 50 μl stop solution were added before the determination. Autologous tumor cells were targeted used. Each experiment was carried out in triplicate and an average was formed. The lytic unit (LU) was determined by titration curves. An LU is defined as the number of effector cells that are required to achieve a 10% lysis of 10 ⁴ target cells.

Proliferation assay

The proliferation test "Easy for you" (Biomedica, Vienna, Austria) was used to determine the proliferation of the peripheral blood lymphocytes (PBL), which were taken from the patients before, during and after the treatment. PBL were determined from peripheral blood Ficoll density gradient centrifugation obtained and analyzed according to the protocol using a chromophoric substrate solution with the aid of a spectrophotometer (ELISA reader). The incubation with the substrate solution was carried out for four hours, depending on the metabolic performance of the cells. Converted derivative, the absorption maximum is at 490 nm. The experiments were carried out in triplicate and averaged.

Enzyme immunological test

Cytokine levels in the patient's sera from day 0, 14, 28, 56 and 84 were determined by an enzyme test (ELISA). The IL-7 ELISA kit purchased from Laboserv (Staufenberg, Germany); the R&D Systems IFN-gamma, TNF-alpha and TGF-beta1 ELISA kit (Quantikine, Minneapolis, Minnesota); and the GM-CSF-ELISA from Promocell (Heidelberg, Germany). Soluble IL-7, IFN-gamma, TNF-alpha, TGF-beta1 and GM-CSF in concentrations of 9, 3, 4.4, 7, 1.5 pg / ml to 1000, 500, 500, 1000, 500 pg / ml could be used be determined. The microtiter plates were coated with a monoclonal AK, which bound the cytokines after incubation in the serum. After several washing steps to

Removing the unbound protein, an enzyme-coupled (Merrettich-Peroxidase) polyclonal AK was added, which bound the cytokines in the liquid phase. After washing, the substrate solution was added and the color development was monitored at a wavelength λ = 450 nm. The optical density of the samples was comparable to the calibration curve. To generate the Calibration curve were standard samples according to WHO standards were used.

Hypersensitivity reaction

A commercially available delayed type hypersensitivity (DTH) test (Multi Test Merieux, Leimen, Germany) was used before and after the treatment. A positive skin reaction was a hardening occurring within 48 h if its mean diameter was greater than 5 mm.

Preparation of the autologous lymphocytes

Peripheral blood monocytes (PBMC) were obtained from heparinized peripheral blood using lymphoprep (GIBCO, Karlsruhe, Germany) using density centrifugation. The cells were washed twice with PBS and freeze-dried in liquid nitrogen in the presence of more than 20% FCS for ELISPOT and cytotoxic assays.

ELISPOT assay

A HATF multititer plate (Millipore, Eschborn, Germany) was dissolved with 500ng anti-lFN-gamma antibody (AK) (Biozol, Eching, Germany) in coating solution (3.8g / l NaHCO _3, 1.9g / l Na ₂ CO ₃ ), coated at 4 ° C overnight. After washing three times, the plate was blocked with 200 μl blocking solution (5% BSA in phosphate buffer) at 37 ° C. for 30 min. After washing, 10 ⁵ peripheral blood lymphocytes were applied per well and incubated overnight (at 37 ° C, 5%

C0 ₂ ). The plate was washed and incubated with 500ng of a second biotin-labeled IFN-gamma-AK (Biozol) overnight at 4 ° C. Avidin and BCIP / NBT solution (Sigma, Deisenhofen, Germany) were used for the detection.

Statistical analysis

Wilcoxon's customized pairwise and unpaired test was used to analyze the statistical significance. A p-value <.0.05 is considered significant.

Claims

claims

1. Vaccine for the treatment of patients with defined tumor diseases, consisting of a patient's tumor cells, these tumor cells having previously been transfected ex vivo with nucleic acid molecules coding for interleukin-7 (IL-7) and macrophage activating factor (GM-CSF).

2. Vaccine according to claim 1, wherein the nucleic acid molecules coding for interleukin-7 (IL-7) and macrophage activating factor (GM-CSF) are present in one or more expression constructs.

3. Vaccine according to claim 2, wherein the expression construct is a plasmid.

4. Vaccine according to claim 2, wherein the expression construct is a linear, double-stranded, covalently closed expression cassette which consists only of a CMV promoter, an intron which is responsible for interleukin-7 (IL-7) and / or macrophage-activating factor (GM-CSF) coding gene sequence and a polyadenylation sequence, which is closed at both ends of the double strand by a short loop of single-stranded nucleoside residues.

5. Vaccine according to one or more of claims 1 to 4, which additionally comprises immunomodulating oligodeoxyribonucleotides as adjuvant.

6. Vaccine according to claim 5, wherein the immunomodulating oligodeoxyribonucleotide

a) comprises a sequence with the base sequence N ¹ N ² CGN ³ N ⁴ , where N ¹ N ^{2 is} an element selected from the group comprising GT, GG, GA, AT or AA, N ³ N ^{4 is} an element selected from the group comprising CT or TT, and C is deoxycytosine, G deoxyguanosine, A deoxyadenosine and T deoxythymidine,

b) and a circular strand of deoxyribonucleic acid with a partially complementary, antiparallel base sequence and is dumbbell-shaped.

7. Vaccine according to claim 4 and 6, wherein the sequence with the base sequence N ¹ N ² CGN ³ N ^{4 is positioned} in the single-stranded region of the oligodeoxyribonucleotide and comprises 40 to 200 nucleotides.

8. Vaccine according to one or more of claims 1 to 7, which comprises a pharmaceutically acceptable carrier.

9. Vaccine according to claim 1, wherein the cells are selected from renal carcinoma cells, malignant melanoma cells and / or colon carcinoma cells.

10. A method for producing a medicament according to claims 1 to 9 for the treatment of patients with defined tumor diseases, wherein tumor cells of a patient ex vivo with nucleic acid molecules coding for interleukin-7 (IL-7) and macrophage activating factor (GM-CSF) be transfected, immunomodulating oligodeoxyribonucleotides (d-SLIM) are used as adjuvants and then converted into an application-ready pharmaceutical composition.

11. The method of claim 10, wherein the tumor disease is a

Colon cancer, renal cell carcinoma and / or malignant melanoma.

12. The method according to claim 11, wherein the tumor cells originate from several patients with the same tumor disease.

13. The method according to at least one of claims 10 to 12, wherein the immunomodulating oligodeoxyribonucleotide forms a circular strand of deoxy comprises ribonucleic acid with a mutually complementary, antiparallel base sequence and is dumbbell-shaped.

14. The method according to claim 13, wherein the immunomodulating oligodeoxyribonucleotide comprises a sequence with the base sequence N ¹ N ² CGN ³ N ⁴ , where N ¹ N ^{2 is} an element selected from the group comprising GT, GG, GA, AT or AA, N ³ N ^{4 is} an element selected from the group comprising CT or TT, and C deoxycytosine, G deoxyguanosine, A deoxyadenosine and T deoxythymidine.

15. The method according to claim 14, wherein the sequence with the base sequence N ¹ N ² CGN ³ N ^{4 is positioned} in the single-stranded region of the oligodeoxyribonucleotide and comprises 40 to 200 nucleotides.

16. The method of claim 10, wherein the nucleic acid molecules are present in one or more expression constructs.

17. The method according to one or more of claims 10 to 16, characterized in that the transfection takes place by means of ballistic transfer, polycation transfection, calcium phosphate precipitation, microinjection, protoplast fusion, liposome fusion, viral transfection systems, lipofection and / or electroporation ,

18. The method according to claim 10, wherein the tumor diseases are cytokine-related diseases, in particular malignant or benign tumors.